The most commonly used molecular-targeted drugs for HER2-positive breast cancer include tucatinib4, trastuzumab5, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1)6,7. The gene discussed is ERBB2; the disease is breast cancer.